Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 14. Int J Mol Sci. 2019 Jan 4;20(1):170. doi: 10.3390/ijms20010170. Therapeutic Targets for Bone and Soft-Tissue Sarcomas. Miwa S(1), Yamamoto N(2), Hayashi K(3), Takeuchi A(4), Igarashi K(5), Tsuchiya H(6). Author information: (1)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. smiwa001@yahoo.co.jp. (2)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. norinori@med.kanazawa-u.ac.jp. (3)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. khayashi830@gmail.com. (4)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. a_take@med.kanazawa-u.ac.jp. (5)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. kenken99004@yahoo.co.jp. (6)Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. tsuchi@med.kanazawa-u.ac.jp. Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into molecular targets and new treatments has been particularly challenging. Although intensive chemotherapy and establishment of surgical procedures have improved the outcomes of patients with sarcoma, the curative rate of recurrent and metastatic sarcomas is still not satisfactory. Recent basic science research has revealed some of the mechanisms of progression and metastasis of malignancies including proliferation, apoptosis, angiogenesis, tumor microenvironment, migration, invasion, and regulation of antitumor immune systems. Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas. DOI: 10.3390/ijms20010170 PMCID: PMC6337155